Bourgeon Capital Management LLC Sells 71,313 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bourgeon Capital Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 48.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 76,753 shares of the biopharmaceutical company's stock after selling 71,313 shares during the quarter. Bourgeon Capital Management LLC's holdings in Gilead Sciences were worth $6,218,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Altshuler Shaham Ltd increased its stake in shares of Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company's stock worth $159,000 after acquiring an additional 121 shares during the last quarter. Nilsine Partners LLC increased its stake in shares of Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company's stock worth $891,000 after acquiring an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. increased its stake in shares of Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company's stock worth $1,486,000 after acquiring an additional 128 shares during the last quarter. Financial Counselors Inc. increased its position in Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company's stock worth $718,000 after buying an additional 128 shares during the last quarter. Finally, Revolve Wealth Partners LLC grew its position in shares of Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company's stock valued at $292,000 after purchasing an additional 130 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Down 0.5 %

NASDAQ:GILD traded down $0.32 during trading hours on Monday, hitting $67.75. 7,714,373 shares of the company were exchanged, compared to its average volume of 7,380,445. The stock has a market capitalization of $84.35 billion, a price-to-earnings ratio of 15.06, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a one year low of $67.62 and a one year high of $87.86. The company has a fifty day simple moving average of $72.79 and a 200 day simple moving average of $76.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.08 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.55%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 68.44%.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Barclays reduced their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating for the company in a research note on Monday, February 12th. Truist Financial cut shares of Gilead Sciences from a "buy" rating to a "hold" rating and cut their price target for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Mizuho cut their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company cut their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating for the company in a research note on Monday, March 4th. Finally, Oppenheimer lowered their price target on shares of Gilead Sciences from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $85.36.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company's stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the sale, the chief financial officer now owns 101,534 shares in the company, valued at $8,709,586.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,000 shares of company stock valued at $721,180. Company insiders own 0.16% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.